Summary
Mitochondria are involved in energetic, biosynthetic, and homeostatic processes in eukaryotic cells. Mitochondria carry their own circular genome and disruption of the quantity or quality of mitochondrial genome is associated with various aging-related diseases1–3. Unlike the nuclear genome, mitochondrial DNA (mtDNA) can be present at 1,000s to 10,000s copies in somatic cells and variants may exist in a state of heteroplasmy, where only a fraction of the DNA molecules harbor a particular variant. We used MitoHPC, a bioinformatics pipeline, to accurately quantify mtDNA heteroplasmy from whole genome sequencing data in 194,871 participants in the UK Biobank. We found that the presence of heteroplasmy is associated with an increased risk of all-cause mortality (adjusted hazard ratio [aHR] 1.50-fold; 95% confidence interval [CI] 1.14, 1.98, when comparing participants with 4 or more heteroplasmies to those without any heteroplasmy). In addition, we functionally characterized mtDNA single nucleotide variants (SNVs) using a novel constraint-based score, Mitochondrial local constraint (MLC) score sum (MSS), which demonstrated that SNVs at highly constrained sites were strongly associated with all-cause mortality (aHR for a 1-unit increase in MSS 1.28; 95% CI 1.20, 1.37) and cancer-related mortality (aHR 1.36; 95% CI 1.24,1.49), particularly lung and breast cancers, lymphoma, and leukemia. MSS was also associated with prevalence and incidence of lung cancer, lymphoma, and leukemia. Moreover, among individuals with prevalent leukemia, high MSS was strongly associated with leukemia mortality (adjusted HR 4.03; 95% CI 1.34, 12.11). These results indicate that mitochondria may have a functional role in certain cancers and mitochondrial heteroplasmic SNVs have the potential to serve as a prognostic markers for cancer incidence and outcome, especially for leukemia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was conducted using the UK Biobank Resource under Application Number 17731. This work was supported by National Heart, Lung and Blood Institute, National Institutes of Health (NIH) grant R01HL144569, National Health and Medical Research Council Fellowship (1159456) and American Australian Association Scholarship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Johns Hopkins Medicine Institutional Review Boards (IRB) of Johns Hopkins Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data in the present study were obtained directly from the UK Biobank.
